Dolutegravir-based dual maintenance regimens combined with lamivudine/emtricitabine or rilpivirine: risk of virological failure in a real-life setting-Reference-Cited by-同舟云学术

Dolutegravir-based dual maintenance regimens combined with lamivudine/emtricitabine or rilpivirine: risk of virological failure in a real-life setting

Published:2021-10-15 Issue:1 Volume:77 Page:196-204
ISSN:0305-7453
Container-title:Journal of Antimicrobial Chemotherapy
language:en
Short-container-title:

Author:

Deschanvres Colin¹^ORCID,Reynes Jacques²³,Lamaury Isabelle⁴,Rey David⁵,Palich Romain⁶^ORCID,Bani-Sadr Firouzé⁷,Robineau Olivier⁸,Duvivier Claudine⁹,Hocqueloux Laurent¹⁰^ORCID,Cuzin Lise¹¹¹²^ORCID,Joly Veronique¹³,Raffi Francois¹,Cabie André¹²,Allavena Clotilde¹,Chirouze C,Drobacheff-Thiébaut C,Foltzer A,Bouiller K,Hustache- Mathieu L,Lepiller Q,Bozon F,Babre O,Brunel A S,Muret P,Chevalier E,Jacomet C,Laurichesse H,Lesens O,Vidal M,Mrozek N,Aumeran C,Baud O,Corbin V,Goncalvez E,Mirand A,Brebion A,Henquell C,Lamaury I,Fabre I,Curlier E,Ouissa R,Herrmann-Storck C,Tressieres B,Receveur M C,Boulard F,Daniel C,Clavel C,Roger P M,Markowicz S,Chellum Rungen N,Merrien D,Perré P,Guimard T,Bollangier O,Leautez S,Morrier M,Laine L,Boucher D,Point P,Cotte L,Ader F,Becker A,Boibieux A,Brochier C,Brunel-Dalmas F,Cannesson O,Chiarello P,Chidiac C,Degroodt S,Ferry T,Godinot M,Livrozet J M,Makhloufi D,Miailhes P,Perpoint T,Perry M,Pouderoux C,Roux S,Triffault-Fillit C,Valour F,Charre C,Icard V,Tardy J C,Trabaud M A,Ravaux I,Ménard A,Belkhir A Y,Colson P,Dhiver C,Madrid A,Martin-Degioanni M,Meddeb L,Mokhtari M,Motte A,Raoux A,Toméi C,Tissot-Dupont H,Poizot-Martin I,Brégigeon S,Zaegel-Faucher O,Obry-Roguet V,Laroche H,Orticoni M,Soavi M J,Ressiot E,Ducassou M J,Jaquet I,Galie S,Colson H,Ritleng A S,Ivanova A,Debreux C,Lions C,Rojas-Rojas T,Cabié A,Abel S,Bavay J,Bigeard B,Cabras O,Cuzin L,Dupin de Majoubert R,Fagour L,Guitteaud K,Marquise A,Najioullah F,Pierre-François S,Pasquier J,Richard P,Rome K,Turmel J M,Varache C,Atoui N,Bistoquet M,Delaporte E,Le Moing V,Makinson A,Meftah N,Merle de Boever C,Montes B,Montoya Ferrer A,Tuaillon E,Reynes J,Lefèvre B,Jeanmaire E,Hénard S,Frentiu E,Charmillon A,Legoff A,Tissot N,André M,Boyer L,Bouillon M P,Delestan M,Goehringer F,Bevilacqua S,Rabaud C,May T,Raffi F,Allavena C,Aubry O,Billaud E,Biron C,Bonnet B,Bouchez S,Boutoille D,Brunet-Cartier C,Deschanvres C,Gaborit B J,Grégoire A,Grégoire M,Grossi O,Guéry R,Jovelin T,Lefebvre M,Le Turnier P,Lecomte R,Morineau P,Reliquet V,Sécher S,Cavellec M,Paredes E,Soria A,Ferré V,André-Garnier E,Rodallec A,Pugliese P,Breaud S,Ceppi C,Chirio D,Cua E,Dellamonica P,Demonchy E,De Monte A,Durant J,Etienne C,Ferrando S,Garraffo R,Michelangeli C,Mondain V,Naqvi A,Oran N,Perbost I,Carles M,Klotz C,Maka A,Pradier C,Prouvost-Keller B,Risso K,Rio V,Rosenthal E,Touitou I,Wehrlen-Pugliese S,Zouzou G,Hocqueloux L,Prazuck T,Gubavu C,Sève A,Giaché S,Rzepecki V,Colin M,Boulard C,Thomas G,Cheret A,Goujard C,Quertainmont Y,Teicher E,Lerolle N,Jaureguiberry S,Colarino R,Deradji O,Castro A,Barrail-Tran A,Yazdanpanah Y,Landman R,Joly V,Ghosn J,Rioux C,Lariven S,Gervais A,Lescure F X,Matheron S,Louni F,Julia Z,Le Gac S,Charpentier C,Descamps D,Peytavin G,Duvivier C,Aguilar C,Alby-Laurent F,Amazzough K,Benabdelmoumen G,Bossi P,Cessot G,Charlier C,Consigny P H,Jidar K,Lafont E,Lanternier F,Leporrier J,Lortholary O,Louisin C,Lourenco J,Parize P,Pilmis B,Rouzaud C,Touam F,Valantin M A,Tubiana R,Agher R,Seang S,Schneider L,Palich R,Blanc C,Katlama C,Bani-Sadr F,Berger J L,N’Guyen Y,Lambert D,Kmiec I,Hentzien M,Brunet A,Romaru J,Marty H,Brodard V,Arvieux C,Tattevin P,Revest M,Souala F,Baldeyrou M,Patrat-Delon S,Chapplain J M,Benezit F,Dupont M,Poinot M,Maillard A,Pronier C,Lemaitre F,Morlat C,Poisson-Vannier M,Sinteff J P,Gagneux-Brunon A,Botelho-Nevers E,Frésard A,Ronat V,Lucht F,Rey D,Fischer P,Partisani M,Cheneau C,Priester M,Mélounou C,Bernard-Henry C,de Mautort E,Fafi-Kremer S,Delobel P,Alvarez M,Biezunski N,Debard A,Delpierre C,Gaube G,Lansalot P,Lelièvre L,Marcel M,Martin-Blondel G,Piffaut M,Porte L,Saune K,Robineau O,Ajana F,Aïssi E,Alcaraz I,Alidjinou E,Baclet V,Bocket L,Boucher A,Digumber M,Huleux T,Lafon-Desmurs B,Meybeck A,Pradier M,Tetart M,Thill P,Viget N,Valette M,

Affiliation:

1. Infectious Diseases Department, Nantes University Hospital, Nantes, France

2. Infectious and Tropical Diseases Department, Montpellier University Hospital, Montpellier, France

3. UMI 233, Inserm U1175, Montpellier University Hospital, Montpellier, France

4. Department of Infectious and Tropical Diseases, Dermatology, Internal Medicine, University Hospital of Guadeloupe, Pointe-à-Pitre, France

5. Human Immunodeficiency Virus Care Center, Strasbourg University Hospitals, Strasbourg, France

6. Infectious Diseases Department, Pitié-Salpêtrière Hospital, Paris, France

7. Department of Internal Medicine, Clinical Immunology and Infectious Diseases, Reims University Hospital, Reims, France

8. Infectious Diseases Department, Gustave Dron Hospital, Tourcoing, France

9. Infectious and Tropical Diseases Department, Institut Pasteur, Paris, France

10. Department of Infectious and Tropical Diseases, Regional Hospital Center, Orléans, France

11. CERPOP, Inserm UMR1295, Toulouse University, Toulouse, France

12. Infectious Diseases Department, Martinique University Hospital, Fort-de-France, France

13. Infectious and Tropical Diseases Department, Bichat-Claude Bernard University Hospital, Paris, France

Abstract

Abstract Background Maintenance ART with dolutegravir-based dual regimens have proved their efficacy among HIV-1-infected subjects in randomized trials. However, real-life data are scarce, with limited populations and follow-up. Objectives We assessed virological failure (VF) and resistance-associated mutations (RAMs) on dolutegravir maintenance regimens in combination with rilpivirine or with lamivudine or emtricitabine (xTC) and analysed the factors associated with VF. Methods Between 2014 and 2018, all HIV-1-infected adults included in the Dat’AIDS cohort and starting dolutegravir/rilpivirine or dolutegravir/xTC as a maintenance dolutegravir-based dual regimen were selected. VF was defined as two consecutive HIV RNA values >50 copies/mL or a single value >400 copies/mL. We compared cumulative genotypes before initiation of a maintenance dolutegravir-based dual regimen with genotype at VF. Results We analysed 1374 subjects (799 on dolutegravir/rilpivirine and 575 on dolutegravir/xTC) with a median follow-up of 20 months (IQR = 11–31) and 19 months (IQR = 11–31), respectively. VF occurred in 3.8% (n = 30) of dolutegravir/rilpivirine subjects and 2.6% (n = 15) of dolutegravir/xTC subjects. Among subjects receiving dolutegravir/rilpivirine, two genotypes harboured emerging RAMs at VF: E138K on NNRTI (n = 1); and E138K+K101E on NNRTI and N155H on INSTI (n = 1). Among subjects receiving dolutegravir/xTC, no new RAM was detected. The only predictive factor of VF on dolutegravir/rilpivirine was the history of failure on an NNRTI-based regimen (adjusted HR = 2.97, 95% CI = 1.28–6.93). No factor was associated with VF on dolutegravir/xTC. Conclusions In this large real-life cohort, dolutegravir/rilpivirine and dolutegravir/xTC sustained virological suppression and were associated with a low rate of VF and RAM emergence. Careful virological screening is essential before switching to dolutegravir/rilpivirine in virologically suppressed patients with a history of NNRTI therapy.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology,Microbiology (medical)

Link

https://academic.oup.com/jac/article-pdf/77/1/196/41931337/dkab367.pdf

Reference26 articles.

1. 2019 update of the European AIDS Clinical Society guidelines for treatment of people living with HIV version 10.0;Ryom;HIV Med,2020

2. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies;Llibre;Lancet,2018

3. Efficacy and safety of dolutegravir–rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies;Aboud;Lancet HIV,2019

4. Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: phase 3, randomized, noninferiority TANGO study;van Wyk;Clin Infect Dis,2020

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world prevalence of integrase inhibitor resistance and virological failure since adoption as guideline-preferred therapy;Drugs in Context;2024-05-16

2. Sex differences in the effectiveness and tolerability of dolutegravir plus rilpivirine as a switch strategy in people living with HIV;HIV Medicine;2024-02-20

3. A Comprehensive Literature Review of Treatment-Emergent Integrase Resistance with Dolutegravir-Based Regimens in Real-World Settings;Viruses;2023-12-14

4. Efficacy and tolerability of dolutegravir/lamivudine versus dolutegravir/rilpivirine in switching from a three‐drug regimen based on nonnucleoside reverse transcriptase inhibitors: A retrospective cohort study;Journal of Medical Virology;2023-10

5. Therapeutic drug monitoring and virological response at week 48 in a cohort of HIV‐1‐infected patients switching to dolutegravir/rilpivirine dual maintenance therapy (ANRS‐MIE‐BIRIDER study);British Journal of Clinical Pharmacology;2023-09-18